Sponsor

Hangzhou Sciwind Biosciences Co., Ltd.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Hangzhou Sciwind Biosciences Co., Ltd. appears in 13 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials13
Recruiting shown4
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

13 shown
A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)NCT07734311 · lead sponsor · 2026-08-03
RECRUITING
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure TherapyNCT07434050 · lead sponsor · 2026-03-02
RECRUITING
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure TherapyNCT07387094 · lead sponsor · 2026-02-09
RECRUITING
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityNCT07243171 · lead sponsor · 2025-11-18
RECRUITING
A Study of Ecnoglutide Injection in Overweight or Obese Chinese AdolescentsNCT07836270 · lead sponsor · 2026-10-31
NOT_YET_RECRUITING
A Study of XW003 Injection in Chinese Adolescents With ObesityNCT07143227 · lead sponsor · 2025-08-25
COMPLETED
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)NCT07073417 · lead sponsor · 2025-07-28
ACTIVE_NOT_RECRUITING
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or ObesityNCT05813795 · lead sponsor · 2023-04-05
COMPLETED
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMNCT05680129 · lead sponsor · 2023-01-10
COMPLETED
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM PatientsNCT05680155 · lead sponsor · 2022-12-29
COMPLETED
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy AdultsNCT05184322 · collaborator · 2022-04-12
COMPLETED
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With ObesityNCT05111912 · collaborator · 2021-11-30
COMPLETED
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult ParticipantsNCT04389775 · collaborator · 2020-03-29
COMPLETED

Drugs studied in this sponsor's trials

4 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Hangzhou Sciwind Biosciences Co., Ltd. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo3
dulaglutide1
metformin1
Saxenda1

Sponsor roles

lead sponsor10
collaborator3
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.